Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma

Completed

• Conditions: Kidney Cancer
• Interventions: Procedure: Surgery treatment or local tumor destruction.

• Registration Number: NCT06369519
• Lead Sponsor: Peking University First Hospital

Brief Summary

Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are:

What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients?

Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Detailed Description

Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. This cohort study aims to identify prognostic factors, construct predictive nomograms, and optimize surgical treatment for sporadic BRCC patients. The main questions it aims to answer are:

What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? In this retrospective population-based cohort study, patients diagnosed with sporadic BRCC between 2000 and 2020 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Study Timeline

• Study Start: 2000-01-01
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31
• Status Verified: 2024-04
• Study First Submitted: 2024-04-10
• Study First Submitted QC: 2024-04-12
• Last Update Submitted: 2024-04-12
• Study First Posted: 2024-04-17
• Last Update Posted: 2024-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3677

Inclusion Criteria

• Age ≥ 18 years.
• Clinical diagnosis of localized BRCC (M0) from 2000 to 2020.
• Active follow-up.
• Complete clinicopathological information.

Exclusion Criteria

• Diagnosed by autopsy or death certificate only.
• Tending to suffer from hereditary RCC, including those complicating with pancreatic neuroendocrine tumor (pNET) or hemangioblastoma.
• Unavailable key information.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Synchronous BRCC patients	Surgery treatment or local tumor destruction.	Synchronous BRCC is defined as the second primary RCC emerges within 6 months from the diagnosis of the first primary RCC.
Metachronous BRCC patients	Surgery treatment or local tumor destruction.	Metachronous BRCC develops beyond 6 months from the diagnosis of the first primary RCC.

Primary Outcome Measures

Name	Time	Method
Overall survival (OS)	From date of diagnosis of the second primary RCC until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 20 years.	OS was calculated as the time interval from the diagnosis of the second primary RCC to death or the time to the last follow-up.

Secondary Outcome Measures

Name	Time	Method
Cancer-specific survival (CSS)	From date of diagnosis of the second primary RCC until the date of death from the same disease or the date of last follow-up, whichever came first, assessed up to 20 years.	CSS was calculated as the time interval from the diagnosis of the second primary RCC to death from the same disease or the last follow-up.

Trial Locations

Locations (1)

Peking University First Hospital; 🇨🇳 Beijing, Beijing, China